Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1083 combination influenza and COVID-19 vaccine in healthy adults
NCT05827926Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Apr 2023
- Primary completion
- Dec 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of mCOMBRIAX in influenza and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Moderna Inc. Primary endpoints: Solicited Local and Systemic Adverse Reactions at 7 days, Unsolicited Adverse Events and Severe Adverse Events at 28 days and 7 more. Started Apr 2023; status: completed.
02
Drugs
mCOMBRIAX
03
Conditions
influenzacoronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05827926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05827926.